EGRIFTA WR TM Dosing and Administration 1,2 Once-weekly reconstitution for simpler daily administration EGRIFTA WR TM is a once-daily subcutaneous injection
BPC-157 Peptide 5mg is strictly supplied for laboratory research and in-vitro studies only
Reduced Joint Pain & Inflammation: Both peptides exhibit strong anti-inflammatory properties, reducing discomfort and stiffness associated with arthritis, injury, or overuse
Mild, short-lived reactions can include soreness at the injection site, a brief flushing sensation, mild bruising, or, very rarely, mild nausea
Dosage variations : Vials range from 1 mg to 24 mg, depending on the brand and intended use
Secure sealed packaging